Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis

被引:28
作者
van der Meulen, MFG
Hoogendijk, JE
Moons, KGM
Veldman, H
Badrising, UA
Wokke, JHJ
机构
[1] Univ Utrecht, Med Ctr, Dept Neurol, Div Neuromuscular Disorders, NL-3584 CX Utrecht, Netherlands
[2] Univ Utrecht, Med Ctr, Julius Ctr Gen Practice & Patient Oriented Res, NL-3584 CX Utrecht, Netherlands
[3] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands
关键词
inclusion body myositis; polymyositis; diagnostic test; rimmed vacuoles; SMI-31;
D O I
10.1016/S0960-8966(00)00219-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Problems in diagnosing sporadic inclusion body myositis may arise if ail clinical features fit a diagnosis of polymyositis, but the muscle biopsy shows some rimmed vacuoles. Recently, immunohistochemistry with an antibody directed against phosphorylated neurofilament (SMI-31) has been advocated as a diagnostic test for sporadic inclusion body myositis. The aims of the present study were to define a quantitative criterion to differentiate sporadic inclusion body myositis from polymyositis based on the detection of rimmed vacuoles in the haematoxylin-eosin staining and to evaluate the additional diagnostic value of the SMI-31 staining. Based on clinical criteria and creatine kinase levels in patients with endomysial infiltrates, 18 patients complied with the diagnosis of sporadic inclusion body myositis, and 17 with the diagnosis of polymyositis. A blinded observer counted the abnormal fibres in haematoxylin-eosin-stained sections and in SMI-31-stained sections. The optimal cut-off in the haematoxylin-eosin test was 0.3% vacuolated fibres. Adding the SMI-31 staining significantly increased the positive predictive value from 87 to 100%, but increased the negative predictive value only to small extent. We conclude that (1) patients with clinical and laboratory features of polymyositis, including response to treatment, may show rimmed vacuoles in their muscle biopsy and that (2) adding the SMI-31 stain can be helpful in differentiating patients who respond to treatment from patients who do not. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:447 / 451
页数:5
相关论文
共 15 条
[1]   Inclusion body myositis: Clinical and pathological boundaries [J].
Amato, AA ;
Gronseth, GS ;
Jackson, CE ;
Wolfe, GI ;
Katz, JS ;
Bryan, WW ;
Barohn, RJ .
ANNALS OF NEUROLOGY, 1996, 40 (04) :581-586
[2]   Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis [J].
Askanas, V ;
Alvarez, RB ;
Mirabella, M ;
Engel, WK .
ANNALS OF NEUROLOGY, 1996, 39 (03) :389-391
[3]   INCLUSION BODY MYOSITIS PRESENTING AS TREATMENT-RESISTANT POLYMYOSITIS [J].
CALABRESE, LH ;
MITSUMOTO, H ;
CHOU, SM .
ARTHRITIS AND RHEUMATISM, 1987, 30 (04) :397-403
[4]   CLINICAL HETEROGENEITY AND TREATMENT RESPONSE IN INCLUSION BODY MYOSITIS [J].
COHEN, MR ;
SULAIMAN, AR ;
GARANCIS, JC ;
WORTMANN, RL .
ARTHRITIS AND RHEUMATISM, 1989, 32 (06) :734-740
[5]   POLYMYOSITIS, DERMATOMYOSITIS, AND INCLUSION-BODY MYOSITIS [J].
DALAKAS, MC .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (21) :1487-1498
[6]   RIMMED VACUOLES [J].
FUKUHARA, N ;
KUMAMOTO, T ;
TSUBAKI, T .
ACTA NEUROPATHOLOGICA, 1980, 51 (03) :229-235
[7]   INCLUSION-BODY MYOSITIS AND MYOPATHIES [J].
GRIGGS, RC ;
ASKANAS, V ;
DIMAURO, S ;
ENGEL, A ;
KARPATI, G ;
MENDELL, JR ;
ROWLAND, LP .
ANNALS OF NEUROLOGY, 1995, 38 (05) :705-713
[8]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[9]   THE TREATMENT OF INCLUSION-BODY MYOSITIS - A RETROSPECTIVE REVIEW AND A RANDOMIZED, PROSPECTIVE TRIAL OF IMMUNOSUPPRESSIVE THERAPY [J].
LEFF, RL ;
MILLER, FW ;
HICKS, J ;
FRASER, DD ;
PLOTZ, PH .
MEDICINE, 1993, 72 (04) :225-235
[10]  
MIKOL J, 1994, MYOLOGY, P1384